Cell-permeable, irreversible inhibitor of caspase-3/CPP32; inhibits tumor cell apoptosis. Neuroprotective in rat hippocampus following seizures in vivo.

CeMMEC1 is a novel potent inhibitor of the second bromodomain of TAF1, binding neither the first nor the second bromodomain of BRD4.

Cenicriviroc is an orally active, dual CCR2/CCR5 antagonist, and displays potent anti-inflammatory and aninfective activity.

Centrinone is a selective and reversible inhibitor of polo-like kinase 4 (Plk4), a serine-threonine protein kinase that initiates centriole/centrosome assembly.

CEP-28122 is a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.

CEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2.

CEP33779(< 3 μM) inhibits phosphorylation of downstream target signal transducer and activator of transcription 5(pSTAT5) of JAK2 in a concentration dependent manner in HEL92 cells.

CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).

CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively.

Cephalosporin C Na salt is used to study the effect of transpeptidase expression, binding, and inhibition on bacterial cell wall mucopeptide synthesis.

Cephalosporin C zinc salt is used to study the effect of transpeptidase expression, binding, and inhibition on bacterial cell wall mucopeptide synthesis.

Cephalotaxine is an antiviral as well as antitumor agent.

CERC-501(LY-2456302) is a potent, selective antagonist of the kappa opioid receptor (KOR) (Ki = 0.81 nM vs. 24.0 nM and 155 nM for the μ-opioid receptor (MOR) and δ-opioid receptor (DOR), respectively.

Cerdulatinib(PRT-062070; PRT2070) is an novel oral dual Syk/JAK inhibitor.

Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome.

CF-102(2-Cl-IB-MECA) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively. target: A3 adenosine receptor agonist;

CFI-400437 is potent against PLK4 (IC50 = 0.6 nM) and selective against other members of the PLK family (>10 uM).

c-FMS-IN-8 is a potent, selective c-FMS kinase inhibitor with IC50 of 0.8 nM, shows activity in collagen-induced model of arthritis in mice..

CFTR Inhibitor II is a cell-permeable glycinyl hydrazone compound that acts as a potent, selective and reversible open-channel blocker of CFTR with intermediate speed (< 1 min; 95% inhibition at 50 µM; Ki = 4.3 µM in CFTR-expressing FRT cells.

CG-806 (CG806, CG'806) is a novel potent, pan-FLT3/BTK multi-kinase inhibitor with impressive inhibition of leukemic cell proliferation with IC50 at sub-nanomolar or low nanomolar levels.

CGI1746 is a small-molecule Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.

CGK 733 is a potent and selective inhibitor of ATM/ATR with IC50 of ~200 nM.